Literature DB >> 19060543

Epstein-Barr virus, rapamycin, and host immune responses.

Sheri M Krams1, Olivia M Martinez.   

Abstract

PURPOSE OF REVIEW: To summarize recent advances that contribute to our understanding of the pathobiology of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD), the host immune response to virally infected B cells, and the molecular basis for the effects of mammalian target of rapamycin inhibitors on EBV+ B-cell lymphomas. RECENT
FINDINGS: Cytogenetic and genomic analyses support the concept that the underlying biology of EBV-associated PTLD is complex. Transplant recipients can generate and maintain significant populations of EBV-specific CD8+ memory T cells but the function of these cells may be impaired. EBV invokes multiple strategies to subvert and evade the host immune response. The phosphoinositide-3 kinase/Akt/mammalian target of rapamycin signal transduction pathway is a nexus for growth and survival signals in PTLD-associated EBV+ B-cell lymphomas.
SUMMARY: Multiple factors influence the development of EBV-associated PTLD including the host immune response to EBV, virally induced effects on the infected cell and the host immune system, and the type and intensity of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060543      PMCID: PMC2650428          DOI: 10.1097/MOT.0b013e3283186ba9

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  43 in total

1.  Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.

Authors:  Natalie Motsch; Thorsten Pfuhl; Jan Mrazek; Stephanie Barth; Friedrich A Grässer
Journal:  RNA Biol       Date:  2007-11       Impact factor: 4.652

2.  Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.

Authors:  M Boratyńska; E Watorek; D Smolska; D Patrzałek; M Klinger
Journal:  Transplant Proc       Date:  2007-11       Impact factor: 1.066

3.  Proteomics analysis in post-transplant lymphoproliferative disorders.

Authors:  Yazan Alsayed; Xavier Leleu; Alexey Leontovich; Ana B Oton; Mona Melhem; Diane George; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2008-07-28       Impact factor: 2.997

4.  The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function.

Authors:  Jianmin Zuo; Wendy Thomas; Daphne van Leeuwen; Jaap M Middeldorp; Emmanuel J H J Wiertz; Maaike E Ressing; Martin Rowe
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

5.  A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.

Authors:  Amy E Guppy; Eira Rawlings; J Alejandro Madrigal; Peter L Amlot; Linda D Barber
Journal:  Transplantation       Date:  2007-12-15       Impact factor: 4.939

6.  Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.

Authors:  R A McDonald; J M Smith; M Ho; R Lindblad; D Ikle; P Grimm; R Wyatt; M Arar; D Liereman; N Bridges; W Harmon
Journal:  Am J Transplant       Date:  2008-05       Impact factor: 8.086

7.  EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3.

Authors:  Tianli Xia; Andrea O'Hara; Iguaracyra Araujo; Jose Barreto; Eny Carvalho; Jose Bahia Sapucaia; Juan Carlos Ramos; Estela Luz; Celia Pedroso; Michele Manrique; Ngoc L Toomey; Carlos Brites; Dirk P Dittmer; William J Harrington
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

8.  Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

Authors:  A D Kirk; W S Cherikh; M Ring; G Burke; D Kaufman; S J Knechtle; S Potdar; R Shapiro; V R Dharnidharka; H M Kauffman
Journal:  Am J Transplant       Date:  2007-09-14       Impact factor: 8.086

9.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Authors:  Stephan Sauer; Ludovica Bruno; Arnulf Hertweck; David Finlay; Marion Leleu; Mikhail Spivakov; Zachary A Knight; Bradley S Cobb; Doreen Cantrell; Eric O'Connor; Kevan M Shokat; Amanda G Fisher; Matthias Merkenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

10.  The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells.

Authors:  Sokol Haxhinasto; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2008-02-18       Impact factor: 14.307

View more
  17 in total

Review 1.  Autophagy: a primer for the gastroenterologist/hepatologist.

Authors:  Christiane Sokollik; Michelle Ang; Nicola Jones
Journal:  Can J Gastroenterol       Date:  2011-12       Impact factor: 3.522

2.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

Review 3.  Translation inhibition and stress granules in the antiviral immune response.

Authors:  Craig McCormick; Denys A Khaperskyy
Journal:  Nat Rev Immunol       Date:  2017-06-26       Impact factor: 53.106

Review 4.  Post Transplant Lymphoproliferative Disorder.

Authors:  Devika Gupta; Satish Mendonca; Sushmita Chakraborty; Tathagata Chatterjee
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-17       Impact factor: 0.900

Review 5.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Authors:  Nishitha Reddy; Katayoun Rezvani; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-21       Impact factor: 5.742

6.  Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

Authors:  C Cutler; K Stevenson; H T Kim; J Brown; S McDonough; M Herrera; C Reynolds; D Liney; G Kao; V Ho; P Armand; J Koreth; E Alyea; B R Dey; E Attar; T Spitzer; V A Boussiotis; J Ritz; R Soiffer; J H Antin; K Ballen
Journal:  Bone Marrow Transplant       Date:  2010-08-09       Impact factor: 5.483

Review 7.  Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.

Authors:  Vidhya Murukesan; Sandeep Mukherjee
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

8.  PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.

Authors:  S Furukawa; L Wei; S M Krams; C O Esquivel; O M Martinez
Journal:  Am J Transplant       Date:  2013-07-10       Impact factor: 8.086

Review 9.  Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

Review 10.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.